The world's largest AstraZeneca plant will be built in the United States. The company will invest $50 billion in the country

The British-Swedish pharmaceutical company AstraZeneca plans to invest $50 billion to expand its production and research facilities in the United States by 2030. About writes Reuters.

The money will be used to build a new drug manufacturing plant in Virginia, as well as to expand cell therapy research and development centers in Maryland, Massachusetts, California, Indiana, and Texas.

The company is also modernizing its drug supply network for clinical trials in the United States and will continue to invest in the development of new medicines.

AstraZeneca explains that the expansion will help achieve its strategic goal of increasing annual revenues to $80 billion by 2030, of which half should come from sales in the United States.

The investment decision coincided with the strengthening of the administration's policy Donald Trump to support national production.

The US president is calling on pharmaceutical companies to produce more drugs domestically instead of importing them. He also insists that other countries should pay more for innovative drugs, partially offsetting the US spending on research and development.

AstraZeneca will build the largest manufacturing facility in the company's history in Virginia. It will produce active ingredients for promising weight loss and cholesterol-lowering drugs.

According to the company, the investment will potentially create tens of thousands of jobs. AstraZeneca currently employs about 18,000 people in the US and 90,000 globally.

The announcement of the new financing follows a previously announced $3.5 billion investment announced in November 2024.

• AstraZeneca has lost status of the most expensive company in Britain after Trump's promise reduce prices for medicines.